Diffusion-Weighted MRI in the Evaluation of Early-Stage Breast Cancer Treated with a Short Preoperative Radiotherapy: Preliminary Results.

Autor: Hottat N; University Hospital Brugmann, BE., Jani J; University Hospital Brugmann, BE., Badr D; University Hospital Brugmann, BE., Ridder M; UZ Brussel, BE., Nazac A; University Hospital Brugmann, BE., Houte KV; University Hospital Brugmann, BE., Lecomte S; University Hospital Brugmann, BE., Cannie M; University Hospital Brugmann, BE.
Jazyk: angličtina
Zdroj: Journal of the Belgian Society of Radiology [J Belg Soc Radiol] 2023 Feb 07; Vol. 107 (1), pp. 8. Date of Electronic Publication: 2023 Feb 07 (Print Publication: 2023).
DOI: 10.5334/jbsr.2815
Abstrakt: Objective: To assess tumor response with diffusion-weighted MRI (DW-MRI) after a short preoperative radiotherapy in early-stage breast cancer (BCa).
Materials and Methods: This was a prospective, single-center pilot study. 3T-MRI were performed before and after radiotherapy. The longest diameter (LD) and the apparent diffusion coefficient (ADC) value of a region of interest (ROI) of the tumors were recorded. Histopathology and immunohistochemistry, including the Ki-67 index of the core biopsy and of the surgical specimen, were the reference standards.
Results: Nineteen patients with 22 early-stage BCa were included. The mean ROI ADC value was 1.093 ± 0.278 × 10 -3 mm 2 /s before radiotherapy and 1.490 ± 0.429 × 10 -3 mm 2 /s (p-value < 0.001) after radiotherapy. The Ki-67 index was 9.2 ± 9.1% at the percutaneous biopsy before radiotherapy and 4.9 ± 7.5% (p-value = 0.005) after radiotherapy at the surgical specimen. After neoadjuvant radiotherapy, a 4.7% decrease in LD and a 36.3% increase in ROI-ADC of the tumors were measured at MRI and a 46.7% decrease in Ki-67 index was observed at histology of the surgical specimen in comparison with the percutaneous core biopsy.
Conclusion: In early-stage BCa, a significant increase in ROI-ADC at DWI and a significant decrease in Ki-67 index were observed after a short preoperative radiotherapy, suggesting early tumor response.
Competing Interests: The authors have no competing interests to declare.
(Copyright: © 2023 The Author(s).)
Databáze: MEDLINE